These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3895033)

  • 81. Bromocriptine in Parkinson's disease.
    Stern G; Lees A
    Br J Hosp Med; 1978 Dec; 20(6):666-70. PubMed ID: 743580
    [No Abstract]   [Full Text] [Related]  

  • 82. The effect of bromocriptine in patients with benign prostatic hypertrophy.
    Farrar DJ; Pryor JS
    Br J Urol; 1976 Feb; 48(1):73-5. PubMed ID: 57815
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 85. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
    Lieberman AN; Gopinathan G; Pasternack P; Goldstein M
    Adv Neurol; 1990; 53():533-7. PubMed ID: 1978521
    [No Abstract]   [Full Text] [Related]  

  • 87. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group.
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):77-82. PubMed ID: 2651567
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The antiparkinsonian efficacy of bromocriptine.
    Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M
    Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Agonist substitution in advanced Parkinson's disease.
    Goetz CG; Shannon KM; Tanner CM; Carroll VS; Klawans HL
    Neurology; 1989 Aug; 39(8):1121-2. PubMed ID: 2761708
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bromocriptine in Huntington chorea.
    Kartzinel R; Hunt RD; Calne DB
    Arch Neurol; 1976 Jul; 33(7):517-8. PubMed ID: 132915
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pergolide versus bromocriptine.
    Login IS
    Neurology; 1984 Feb; 34(2):258. PubMed ID: 6538025
    [No Abstract]   [Full Text] [Related]  

  • 92. Bromocriptine (ParlodelR) in the treatment of Parkinson's disease.
    Molina-Negro P; Grimes JD; Jones MW; Kofman OS; Bouchard S
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):503-8. PubMed ID: 6761765
    [No Abstract]   [Full Text] [Related]  

  • 93. Bromocriptine--lisuride cross tolerance.
    Giovannini P; Scigliano G; Grassi MP; Carella F; Parati E; Caraceni T
    Ital J Neurol Sci; 1983 Apr; 4(1):129-30. PubMed ID: 6862842
    [No Abstract]   [Full Text] [Related]  

  • 94. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine.
    Kains JP; Hardy JC; Chevalier C; Collier A
    Acta Clin Belg; 1990; 45(5):306-10. PubMed ID: 2177299
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Letter: Growth-hormone response to bromocriptine in parkinsonism.
    Shaw KM; Lees AJ; Hayes S; Ross EJ; Stern GM; Thompson BD
    Lancet; 1976 Jan; 1(7952):194. PubMed ID: 54702
    [No Abstract]   [Full Text] [Related]  

  • 96. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.
    Demonet JF; Rostin M; Dueymes JM; Ioualalen A; Montastruc JL; Rascol A
    Clin Neuropharmacol; 1986; 9(2):200-1. PubMed ID: 3708605
    [No Abstract]   [Full Text] [Related]  

  • 97. Parkinson's disease and hypertension: chronic bromocriptine treatment.
    Montastruc JL; Chamontin B; Rascol A
    Neurology; 1985 Nov; 35(11):1644-7. PubMed ID: 4058753
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Treatment of Huntington's chorea with bromocriptine.
    Frattola L; Albiazzati MG; Spano PF; Trabucchi M
    Acta Neurol Scand; 1977 Jul; 56(1):37-45. PubMed ID: 141860
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Low-dose CU 32-085 (mesulergine) in previously untreated Parkinson's disease.
    Bonnet AM; Esteguy M; Guimaraes J; Lhermitte F; Agid Y
    Neurology; 1984 Aug; 34(8):1127-8. PubMed ID: 6540396
    [No Abstract]   [Full Text] [Related]  

  • 100. Double-blind assessment of potential pergolide-induced cardiotoxicity.
    Kurlan R; Miller C; Knapp R; Murphy G; Shoulson I
    Neurology; 1986 Jul; 36(7):993-5. PubMed ID: 3520383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.